Dr Stephan Dreyer

  • Clinical Lecturer- NES (Clinical Research Garscube)
  • Honorary Clinical Lecturer (School of Cancer Sciences)

telephone: 0131 330 2826
email: Stephan.Dreyer@glasgow.ac.uk

Import to contacts

Publications

List by: Type | Date

Jump to: 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017
Number of items: 18.

2023

Dreyer, S. B. et al. (2023) The impact of molecular subtyping on pathological staging of pancreatic cancer. Annals of Surgery, 277(2), e396-e405. (doi: 10.1097/SLA.0000000000005050) (PMID:36745763) (PMCID:PMC9831035)

2022

Bryce, A. S. , Dreyer, S. B., Froeling, F. E.M. and Chang, D. K. (2022) Exploring the biology of cancer-associated fibroblasts in pancreatic cancer. Cancers, 14(21), 5302. (doi: 10.3390/cancers14215302) (PMID:36358721) (PMCID:PMC9659154)

Khan, K. S. , Gall, L. S., Dreyer, S., McCollum, C., Chuntamongkol, R., Craig, C., MacKay, C., Macdonald, A. and Forshaw, M. (2022) Stage migration in newly diagnosed oesophagogastric cancer during the first wave of the COVID-19 pandemic. British Journal of Surgery, 109(8), pp. 773-774. (doi: 10.1093/bjs/znac112) (PMID:35616120)

Dreyer, S. B., Upstill-Goddard, R., Legrini, A., Biankin, A. V. , Jamieson, N. B. and Chang, D. K. (2022) Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence. Gastroenterology, 162(1), 320-324.e4. (doi: 10.1053/j.gastro.2021.09.022) (PMID:34534536) (PMCID:PMC8721486)

2021

Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)

Dreyer, S. B. et al. (2021) Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology, 160(1), pp. 362-377. (doi: 10.1053/j.gastro.2020.09.043) (PMID:33039466) (PMCID:PMC8167930)

2020

Moekotte, A. L. et al. (2020) Histopathologic predictors of survival and recurrence in resected ampullary adenocarcinoma. Annals of Surgery, 272(6), pp. 1086-1093. (doi: 10.1097/SLA.0000000000003177) (PMID:30628913)

Moekotte, A. L. et al. (2020) Development and external validation of a prediction model for survival in patients with resected ampullary adenocarcinoma. European Journal of Surgical Oncology, 46(9), pp. 1717-1726. (doi: 10.1016/j.ejso.2020.04.011) (PMID:32624291)

Dreyer, S. B. et al. (2020) Precision oncology in surgery: patient selection for operable pancreatic cancer. Annals of Surgery, 272(2), pp. 366-376. (doi: 10.1097/SLA.0000000000003143) (PMID:32675551) (PMCID:PMC7373491)

Moekotte, A.L. et al. (2020) Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. British Journal of Surgery, 107(9), pp. 1171-1182. (doi: 10.1002/bjs.11555) (PMID:32259295)

Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31(6), 107625. (doi: 10.1016/j.celrep.2020.107625) (PMID:32402285)

Dreyer, S.B., Jamieson, N.B. , Cooke, S.L. , Valle, J.W., McKay, C.J., Biankin, A.V. and Chang, D.K. (2020) PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer. Clinical Oncology, 32(1), pp. 1-4. (doi: 10.1016/j.clon.2019.07.011) (PMID:31378449)

Dreyer, S.B., Jamieson, N.B. , Morton, J.P. , Sansom, O.J. , Biankin, A.V. and Chang, D.K. (2020) Pancreatic cancer: from genome discovery to PRECISION-Panc. Clinical Oncology, 32(1), pp. 5-8. (doi: 10.1016/j.clon.2019.08.007) (PMID:31522943)

2019

Halbrook, C. J. et al. (2019) Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metabolism, 29(6), 1390-1399.e6. (doi: 10.1016/j.cmet.2019.02.001) (PMID:30827862) (PMCID:PMC6602533)

Dreyer, S. B. et al. (2019) Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chinese Clinical Oncology, 8(2), 16. (doi: 10.21037/cco.2019.04.06) (PMID:31070037)

2018

Dreyer, S.B., Jamieson, N.B. , Upstill-Goddard, R., Bailey, P.J. , McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V. and Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105(2), e183-e191. (doi: 10.1002/bjs.10772) (PMID:29341146) (PMCID:PMC5817249)

2017

Dreyer, S. B., Powell, A. G.M.T., McSorley, S. T. , Waterston, A., Going, J. J., Edwards, J. , McMillan, D. C. and Horgan, P. G. (2017) The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer. Annals of Surgical Oncology, 24(5), pp. 1295-1303. (doi: 10.1245/s10434-016-5684-3) (PMID:27873100)

Dreyer, S. B., Chang, D. K. , Bailey, P. and Biankin, A. V. (2017) Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clinical Cancer Research, 23(7), pp. 1638-1646. (doi: 10.1158/1078-0432.CCR-16-2411) (PMID:28373362)

This list was generated on Mon Dec 4 23:32:04 2023 GMT.
Jump to: Articles
Number of items: 18.

Articles

Dreyer, S. B. et al. (2023) The impact of molecular subtyping on pathological staging of pancreatic cancer. Annals of Surgery, 277(2), e396-e405. (doi: 10.1097/SLA.0000000000005050) (PMID:36745763) (PMCID:PMC9831035)

Bryce, A. S. , Dreyer, S. B., Froeling, F. E.M. and Chang, D. K. (2022) Exploring the biology of cancer-associated fibroblasts in pancreatic cancer. Cancers, 14(21), 5302. (doi: 10.3390/cancers14215302) (PMID:36358721) (PMCID:PMC9659154)

Khan, K. S. , Gall, L. S., Dreyer, S., McCollum, C., Chuntamongkol, R., Craig, C., MacKay, C., Macdonald, A. and Forshaw, M. (2022) Stage migration in newly diagnosed oesophagogastric cancer during the first wave of the COVID-19 pandemic. British Journal of Surgery, 109(8), pp. 773-774. (doi: 10.1093/bjs/znac112) (PMID:35616120)

Dreyer, S. B., Upstill-Goddard, R., Legrini, A., Biankin, A. V. , Jamieson, N. B. and Chang, D. K. (2022) Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence. Gastroenterology, 162(1), 320-324.e4. (doi: 10.1053/j.gastro.2021.09.022) (PMID:34534536) (PMCID:PMC8721486)

Casolino, R. et al. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32(2), pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013) (PMID:33248227) (PMCID:PMC7840891)

Dreyer, S. B. et al. (2021) Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology, 160(1), pp. 362-377. (doi: 10.1053/j.gastro.2020.09.043) (PMID:33039466) (PMCID:PMC8167930)

Moekotte, A. L. et al. (2020) Histopathologic predictors of survival and recurrence in resected ampullary adenocarcinoma. Annals of Surgery, 272(6), pp. 1086-1093. (doi: 10.1097/SLA.0000000000003177) (PMID:30628913)

Moekotte, A. L. et al. (2020) Development and external validation of a prediction model for survival in patients with resected ampullary adenocarcinoma. European Journal of Surgical Oncology, 46(9), pp. 1717-1726. (doi: 10.1016/j.ejso.2020.04.011) (PMID:32624291)

Dreyer, S. B. et al. (2020) Precision oncology in surgery: patient selection for operable pancreatic cancer. Annals of Surgery, 272(2), pp. 366-376. (doi: 10.1097/SLA.0000000000003143) (PMID:32675551) (PMCID:PMC7373491)

Moekotte, A.L. et al. (2020) Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. British Journal of Surgery, 107(9), pp. 1171-1182. (doi: 10.1002/bjs.11555) (PMID:32259295)

Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31(6), 107625. (doi: 10.1016/j.celrep.2020.107625) (PMID:32402285)

Dreyer, S.B., Jamieson, N.B. , Cooke, S.L. , Valle, J.W., McKay, C.J., Biankin, A.V. and Chang, D.K. (2020) PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer. Clinical Oncology, 32(1), pp. 1-4. (doi: 10.1016/j.clon.2019.07.011) (PMID:31378449)

Dreyer, S.B., Jamieson, N.B. , Morton, J.P. , Sansom, O.J. , Biankin, A.V. and Chang, D.K. (2020) Pancreatic cancer: from genome discovery to PRECISION-Panc. Clinical Oncology, 32(1), pp. 5-8. (doi: 10.1016/j.clon.2019.08.007) (PMID:31522943)

Halbrook, C. J. et al. (2019) Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metabolism, 29(6), 1390-1399.e6. (doi: 10.1016/j.cmet.2019.02.001) (PMID:30827862) (PMCID:PMC6602533)

Dreyer, S. B. et al. (2019) Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chinese Clinical Oncology, 8(2), 16. (doi: 10.21037/cco.2019.04.06) (PMID:31070037)

Dreyer, S.B., Jamieson, N.B. , Upstill-Goddard, R., Bailey, P.J. , McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V. and Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105(2), e183-e191. (doi: 10.1002/bjs.10772) (PMID:29341146) (PMCID:PMC5817249)

Dreyer, S. B., Powell, A. G.M.T., McSorley, S. T. , Waterston, A., Going, J. J., Edwards, J. , McMillan, D. C. and Horgan, P. G. (2017) The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer. Annals of Surgical Oncology, 24(5), pp. 1295-1303. (doi: 10.1245/s10434-016-5684-3) (PMID:27873100)

Dreyer, S. B., Chang, D. K. , Bailey, P. and Biankin, A. V. (2017) Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clinical Cancer Research, 23(7), pp. 1638-1646. (doi: 10.1158/1078-0432.CCR-16-2411) (PMID:28373362)

This list was generated on Mon Dec 4 23:32:04 2023 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • The role of cancer associated fibroblast heterogeneity in determining metastatic patterns in pancreatic and oesophageal adenocarcinoma
    Office of the Chief Scientific Adviser
    2022 - 2024
     
  • The role of tumour microenvironment heterogeneity in determining metastatic patterns in pancreatic and oesophagogastric adenocarcinoma
    Rosetrees Trust
    2022 - 2024
     
  • The role of tumour microenvironment heterogeneity in determining metastatic patterns in pancreatic and oesophagogastric adenocarcinoma
    The Stoneygate Trust
    2022 - 2024
     
  • The role of tumour microenvironment heterogeneity in determining metastatic patterns in oesophago-gastric adenocarcinoma
    Tenovus Scotland
    2021 - 2023
     
  • Characterising the immune landscape of molecular subtypes of pancreatic ductal adenocarcinoma
    Cancer Research UK
    2020 - 2022